Phase III

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Sumitovant Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 19, 2020

Details:

The exclusive three-year distribution agreement with aims to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.

Sumitovant Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Lead Product(s): Vibegron,Tolterodine Tartrate

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

52-week post hoc analysis shows Vibegron patients had statistically significant, sustained reduction in UUI and total incontinence episodes compared to active control.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results

Lead Product(s): Vibegron

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Urovant Sciences

Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals

Sumitovant Biopharma

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Urovant Sciences

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Urovant Sciences

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results